Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hepatology Reports

28.02.2024 | Review

Role of Vibration-Controlled Transient Elastography in the Evaluation and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease

verfasst von: Elizabeth E. Williams, Raj Vuppalanchi

Erschienen in: Current Hepatology Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The increasing global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) underscores the urgent need for a reliable non-invasive test (NIT) to phenotype and stratify risk in affected individuals. This narrative review aims to provide clinicians with an understanding of vibration-controlled transient elastography (VCTE). We focus on the clinical significance of key VCTE-derived parameters: the controlled attenuation parameter (CAP), liver stiffness measurement (LSM), and spleen stiffness measurement (SSM).

Recent Findings

VCTE enables simultaneous assessment of hepatic steatosis, fibrosis, and the severity of portal hypertension by measuring CAP, LSM, and SSM, respectively. Furthermore, combination scores improve diagnostic accuracy by reducing values in the indeterminate range. Changes in CAP, LSM, or SSM over time may serve as biomarkers of disease activity.

Summary

CAP, LSM, and SSM, as NITs obtained through VCTE, play pivotal roles in disease phenotyping risk prognostication and monitoring disease progression or treatment response. It is hoped that VCTE-based parameters will minimize or obviate the need for invasive liver biopsy.
Literatur
1.
Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335–47.PubMedCrossRef
2.
Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024;29:101133.
3.
Teng ML, Ng CH, Huang DQ, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29:S32–42.PubMedCrossRef
4.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–57.PubMedCrossRef
5.
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797–835.PubMedCrossRef
6.
Duseja A, Chalasani N. Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD). Hepatol Int. 2013;7(Suppl 2):755–64.PubMedCrossRef
7.
Noureddin M, Ntanios F, Malhotra D, et al. Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017–2018 transient elastography data and application of machine learning. Hepatol Commun. 2022;6:1537–48.PubMedPubMedCentralCrossRef
8.
Younossi ZM, Loomba R, Anstee QM, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68:349–60.PubMedCrossRef
9.
10.
Khalifa A, Rockey DC. The value of liver biopsy and histology in liver disease diagnosis and patient care-a pragmatic prospective clinical practice study. J Clin Gastroenterol. 2023.
11.••
Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161:1657–69. This article provides guidance with recommendations on a clinical pathway for screening at risk patients for MASLD. It encourages a hepatology referral for suspected advanced liver fibrosis in patients with FIB4 > 1.3 and liver stiffness measurements of > 8 kPa determined by elastography.
12.
Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA Clinical Practice Update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2023;165:1080–8.PubMedCrossRef
13.
Vuppalanchi R, Loomba R. Noninvasive tests to phenotype nonalcoholic fatty liver disease: sequence and consequences of arranging the tools in the tool box. Hepatology. 2021;73:2095–8.PubMedCrossRef
14.
Hsu C, Caussy C, Imajo K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. 2019;17(630–637):e638.
15.
Kim BK, Tamaki N, Imajo K, et al. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. J Hepatol. 2022;77:1482–90.PubMedCrossRef
16.
Lazarus JV, Castera L, Mark HE, et al. Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice. JHEP Rep. 2023;5:100596.PubMedCrossRef
17.••
Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(156–163): e152. This prospective study evaluated patients with MASLD who received VCTE measurement within 1 year of liver biopsy (n=393) to determine optimal CAP cutoffs for identifying the presence and severity of hepatic steatosis. CAP values of 285 dB/m differentiates grade 0 vs grades 1-3, 311 dB/m discerns grades 0-1 vs grades 2-3, and 306 dB/m distinguishes grades 0-2 vs grade 3.
18.••
Tamaki N, Kurosaki M, Huang DQ, Loomba R. Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease. Hepatol Res. 2022;52:497–507. This article compares the utility of various NITs in identifying advanced hepatic fibrosis in patients with MASLD. The AUROC of VCTE compared to serum markers for identifying advanced hepatic fibrosis is 0.85-0.88 vs 0.76-0.84 which encourages the use of VCTE in clinical practice given its high diagnostic accuracy.
19.
Vuppalanchi R, Siddiqui MS, Van Natta ML, et al. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology. 2018;67:134–44.PubMedCrossRef
20.
Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.PubMedCrossRef
21.
Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–26.PubMedCrossRef
22.
Tapper EB, Loomba R. Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. Nat Rev Gastroenterol Hepatol. 2018;15:274–82.PubMedPubMedCentralCrossRef
23.
Vuppalanchi R, Sanyal AJ. Myths and mysteries about staging hepatic fibrosis by FibroScan. Clin Gastroenterol Hepatol. 2015;13:780–2.PubMedCrossRef
24.•
Vuppalanchi R, Weber R, Russell S, et al. Is fasting necessary for individuals with nonalcoholic fatty liver disease to undergo vibration-controlled transient elastography? Am J Gastroenterol. 2019;114:995–7. This study evaluated the necessity for fasting prior to VCTE measurement in patients with biopsy proven MASLD (n=24). It demonstrated significantly higher LSM for those fasting for < 2 hours (26 + 25%, p value 0.02). These results established the recommendation of fasting for at least 3 hours prior to VCTE measurement to accurately quantify the degree of hepatic fibrosis.
25.
Taru MG, Neamti L, Taru V, et al. How to identify advanced fibrosis in adult patients with Non-alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Using ultrasound elastography-a review of the literature and proposed multistep approach. Diagnostics (Basel). 2023;13:788.PubMedCrossRef
26.
Ozercan AM, Ozkan H. Vibration-controlled transient elastography in NAFLD: review study. Euroasian J Hepatogastroenterol. 2022;12:S41–5.PubMedPubMedCentral
27.•
Boursier J, Zarski JP, de Ledinghen V, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57:1182–91. This study established the criteria required to identify a reliable VCTE measurement in patients with biopsy proven chronic liver disease (n=1,165). Individuals with IQR/M < 30% and > 10 valid measurements accurately identified 85.8% correctly vs those with IQR/M > 30% identified 69.5% correctly as having chronic liver disease (p value < 0.001). A reliable VCTE measurement consists of a measurement with IQR/M < 30% and > 10 valid measurements.
28.
Berger A, Shili S, Zuberbuhler F, et al. Liver stiffness measurement with FibroScan: use the right probe in the right conditions! Clin Transl Gastroenterol. 2019;10:e00023.PubMedPubMedCentralCrossRef
29.
Uchikawa S, Kawaoka T, Fujino H, et al. The effect of the skin-liver capsule distance on the accuracy of ultrasound diagnosis for liver steatosis and fibrosis. J Med Ultrason. 2001;2022(49):443–50.
30.
de Ledinghen V, Vergniol J, Foucher J, et al. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int. 2010;30:1043–8.PubMedCrossRef
31.
Oeda S, Takahashi H, Imajo K, et al. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan((R)) M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. J Gastroenterol. 2020;55:428–40.PubMedCrossRef
32.
Durango E, Dietrich C, Seitz HK, et al. Direct comparison of the FibroScan XL and M probes for assessment of liver fibrosis in obese and nonobese patients. Hepat Med. 2013;5:43–52.PubMedPubMedCentral
33.
Nogami A, Iwaki M, Kobayashi T, et al. Real-world assessment of SmartExam, a novel FibroScan computational method: a retrospective single-center cohort study. J Gastroenterol Hepatol. 2023;38:321–9.PubMedCrossRef
34.
Collin R, Magnin B, Gaillard C, et al. Prospective study comparing hepatic steatosis assessment by magnetic resonance imaging and four ultrasound methods in 105 successive patients. World J Gastroenterol. 2023;29:3548–60.PubMedPubMedCentralCrossRef
35.
Ganne N, Chazouilleres O, Boursier J, et al. Validation of the continuous controlled attenuation parameter (CAPc) using the MRI-PDFF as reference. J Hepatol. 2022;77:S504.CrossRef
36.
Loree H, Bastard C, Miette V, Sandrin L. Vibration-guided transient elastography: a novel FibroScan(R) examination with improved guidance for liver stiffness measurement. Ultrasound Med Biol. 2020;46:2193–206.PubMedCrossRef
37.
Taru MG, Neamti L, Taru V, et al. How to identify advanced fibrosis in adult patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) using ultrasound elastography-a review of the literature and proposed multistep approach. Diagnostics. 2023;13:788.PubMedPubMedCentralCrossRef
38.
Bedossa P. Current histological classification of NAFLD: strength and limitations. Hepatol Int. 2013;7(Suppl 2):765–70.PubMedCrossRef
39.
Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology. 2016;150(626–637):e627.
40.
Caussy C, Brissot J, Singh S, et al. Prospective, same-day, direct comparison of controlled attenuation parameter with the M vs the XL probe in patients with nonalcoholic fatty liver disease, using magnetic resonance imaging-proton density fat fraction as the standard. Clin Gastroenterol Hepatol. 2020;18(1842–1850):e1846.
41.
Karlas T, Petroff D, Garnov N, et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS ONE. 2014;9:e91987.ADSPubMedPubMedCentralCrossRef
42.•
Vilar-Gomez E, Vuppalanchi R, Gawrieh S, et al. CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population. Hepatology. 2023;77:1241–52. A cohort of 4192 participants underwent LSM and CAP measurements via VCTE to identify a relationship between the degree of LSM and CAP to mortality. This study concluded that LSM (HR: 1.06, 95% CI 1.02-1.11) and CAP (HR 1.01, 95% CI 1.0-1.05) were independently associated with higher mortality rates. In particular, LSM > 9.7 kPa had higher mortality rates than LSM < 9.7 kPa (p < 0.001) and CAP > 285 dB/m was associated with 2.2 fold increase in mortality (95% CI 1.0-4.7).
43.•
Vilar-Gomez E, Vuppalanchi R, Mladenovic A, et al. Prevalence of high-risk nonalcoholic steatohepatitis (NASH) in the United States: results from NHANES 2017–2018. Clin Gastroenterol Hepatol. 2023;21(115–124):e117. This study evaluated the utility of FAST scores in identifying the presence of high-risk MASH in 4,218 individuals who underwent VCTE. FAST scores > 0.35 classified 5.8% of the participants to have high-risk MASH while FAST scores > 0.67 identified 1.2%. These FAST cut-offs can be utilized in determining patients who may be candidates for MASH therapies.
44.
Zhang X, Wang H, Xie X, et al. Outstanding feasibility of spleen stiffness measurement by 100-Hz vibration-controlled transient elastography. JGH Open. 2023;7:387–92.PubMedPubMedCentralCrossRef
45.
Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1717–30.PubMedCrossRef
46.
de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022;76:959–74.PubMedCrossRef
47.
Wong YJ, Zhaojin C, Tosetti G, et al. Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients. Clin Mol Hepatol. 2023;29:135–45.PubMedCrossRef
48.
Pons M, Augustin S, Scheiner B, et al. Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease. Am J Gastroenterol. 2021;116:723–32.PubMedCrossRef
49.
Mladenovic A, Vuppalanchi R, Desai AP. A primer to the diagnostic and clinical utility of spleen stiffness measurement in patients with chronic liver disease. Clin Liver Dis (Hoboken). 2022;19:124–30.PubMedCrossRef
50.
Nagai K, Ogawa Y, Kobayashi T, et al. Gastroesophageal varices evaluation using spleen-dedicated stiffness measurement by vibration-controlled transient elastography. JGH Open. 2022;6:11–9.PubMedCrossRef
51.
Bastard C, Miette V, Cales P, et al. A novel FibroScan examination dedicated to spleen stiffness measurement. Ultrasound Med Biol. 2018;44:1616–26.PubMedCrossRef
52.
Stefanescu H, Marasco G, Cales P, et al. A novel spleen-dedicated stiffness measurement by FibroScan(R) improves the screening of high-risk oesophageal varices. Liver Int. 2020;40:175–85.PubMedCrossRef
53.
Cho YS, Lim S, Kim Y, et al. Spleen stiffness measurement using 2-dimensional shear wave elastography: the predictors of measurability and the normal spleen stiffness value. J Ultrasound Med. 2019;38:423–31.PubMedCrossRef
54.••
Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5:362–73. This cross-sectional study (n=350) established the non-invasive FAST score which combines LSM, CAP, and AST to identify the presence of MASH. Cut-offs > 0.35 has a sensitivity of 0.90 and a cut-off of > 0.67 has a specificity of 0.90 for identifying individuals with MASH.
55.
Sanyal AJ, Foucquier J, Younossi ZM, et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. J Hepatol. 2023;78:247–59.PubMedCrossRef
56.
Noureddin M, Mena E, Vuppalanchi R, et al. Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores. Hepatol Commun. 2023;7.
57.
Pennisi G, Enea M, Pandolfo A, et al. AGILE 3+ score for the diagnosis of advanced fibrosis and for predicting liver-related events in NAFLD. Clin Gastroenterol Hepatol. 2023;21(1293–1302):e1295.
58.
Mozes FE, Lee JA, Vali Y, et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:704–13.PubMedCrossRef
59.
Gidener T, Dierkhising RA, Mara KC, et al. Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD. Hepatology. 2023;77:268–74.PubMedCrossRef
60.
Semmler G, Yang Z, Fritz L, et al. Dynamics in liver stiffness measurements predict outcomes in advanced chronic liver disease. Gastroenterology. 2023;165:1041–52.PubMedCrossRef
61.
Wang JH, Ou HY, Yen YH, et al. Usefulness of controlled attenuation parameter in monitoring clinically relevant decline of hepatic steatosis for non-alcoholic fatty liver disease. Liver Int. 2023;43:1901–8.PubMedCrossRef
62.
Bhattacharyya M, Nickols-Richardson SM, Miller AL, et al. Prevalence and determinants of undiagnosed liver steatosis and fibrosis in a nationally representative sample of US adults. Cureus. 2023;15:e46783.PubMedPubMedCentral
63.
Payne JY, Alkhouri N, Le P, et al. Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017–2018. Hepatol Commun. 2023;7:e0019.PubMedPubMedCentralCrossRef
64.
Graupera I, Thiele M, Ma AT, et al. LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries. BMC Public Health. 2022;22:1385.PubMedPubMedCentralCrossRef
65.
Graupera I, Thiele M, Ma AT, et al. Correction: LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries. BMC Public Health. 2023;23:923.PubMedPubMedCentralCrossRef
Metadaten
Titel
Role of Vibration-Controlled Transient Elastography in the Evaluation and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
verfasst von
Elizabeth E. Williams
Raj Vuppalanchi
Publikationsdatum
28.02.2024
Verlag
Springer US
Erschienen in
Current Hepatology Reports
Elektronische ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-024-00661-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise